Novo Nordisk - An Opportune Time To Book Profits
NVO, which has so far dominated the diabetes market, is expected to face tough times as competition is growing fierce and strong and will unfavorably impact NVO share.
The Motley Fool
How Will This Latest Setback Affect Eli Lilly?
Still struggling to revive its drought of approvals, especially after staunchly refusing to succumb to the rest of Big Pharma's strategy of mergers and acquisitions, Eli Lilly suffered another setback for its diabetes pipeline this week when the FDA rejected Lilly's SGLT2 inhibitor empagliflozin, stating concern with the Boerhringer Ingelheim plant ... (more)
Ask D'Mine: Busting the Pump Control Myth, and Chasing Time
This week, Wil tackles that tough, timeless topic of teenagers with diabetes. Debbie, type 3 from Texas, writes: I have a 19-year-old Type 1 daughter who was diagnosed at age 3. She wore an Animas pump for many years, but during her senior year in high school wanted to go on Lantus because of all the dances, Prom, etc., where she didn't want her ... (more)
Cohort study of insulin glargine and risk of breast, prostate, and...
To examine whether use of insulin glargine, compared with another long-acting insulin, is associated with risk of breast, prostate, colorectal cancer, or all cancers combined.
Adocia Announces Preliminary Positive Clinical Results For Its...
Adocia announces today positive preliminary results for the first clinical trial on an innovative formulation combining insulin analog Glargine , Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, Lispro , Eli Lilly) using Adocia's BioChaperone technology.
Applied Clinical Trials
Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide...
In the AWARD-6 study, once-weekly dulaglutide 1.5 mg achieved the primary endpoint of non-inferiority to once-daily liraglutide 1.8 mg, as measured by the reduction of hemoglobin A1c from baseline at 26 weeks.
The Motley Fool
Poor Pipeline Management Imperils Lilly's Future Cash Flows
Taking big, risky swings is OK for a biotech, but it's generally a poor way to run a big pharma company.
Ask D'Mine: Lantus Mimicking an Insulin Pump?
Happy Saturday, and welcome back to our weekly advice column, Ask D'Mine , hosted by veteran type 1, diabetes author and educator W il Dubois .